Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02638805 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide
A Phase 3 study, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT02638805 is a Phase 3 study that has completed, run by Intarcia Therapeutics. The registered enrollment target is 136 participants.
The verdict
NCT02638805, a Phase 3 study, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
Interventions
- DRUG Metformin
- DRUG Liraglutide
- DRUG ITCA 650 Osmotic Mini Pump 20/60 mcg/day
- DRUG ITCA 650 Osmotic Mini Pump 60 mcg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02638805
The ClinicalTrials.gov registry entry for NCT02638805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin is the first listed.
NCT02638805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02638805 about?
NCT02638805 is a clinical study titled "Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide". A Phase 3b, open-label, randomized, multicenter, safety and tolerability study of ITCA 650 in subjects with Type 2 diabetes taking liraglutide and metformin.
What is the current status of trial NCT02638805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2015-12. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02638805?
The interventions under investigation include: Metformin (DRUG), Liraglutide (DRUG), ITCA 650 Osmotic Mini Pump 20/60 mcg/day (DRUG), ITCA 650 Osmotic Mini Pump 60 mcg/day (DRUG).
Who is sponsoring clinical trial NCT02638805?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.